open access

Vol 54, No 4 (2016)
Original paper
Submitted: 2016-04-14
Accepted: 2016-12-13
Published online: 2016-12-22
Get Citation

Expression of cytokeratin-19 (CK19) in the classical subtype of papillary thyroid carcinoma: the experience of one center in the Silesian region

Krzysztof Kaliszewski, Dorota Diakowska, Marta Strutynska-Karpinska, Marta Rzeszutko, Jedrzej Grzegrzolka, Piotr Dziegiel, Beata Wojtczak, Krzysztof Sutkowski
DOI: 10.5603/FHC.a2016.0025
·
Pubmed: 28051274
·
Folia Histochem Cytobiol 2016;54(4):193-201.

open access

Vol 54, No 4 (2016)
ORIGINAL PAPERS
Submitted: 2016-04-14
Accepted: 2016-12-13
Published online: 2016-12-22

Abstract

Introduction. Cytokeratin-19 (CK19) is recognized as a reliable tumor marker of papillary thyroid carcinoma (PTC). The general prognosis in the classical subtype of PTC (CSTPTC) remains favorable, but some cases can be very aggressive. The aim of this study was to evaluate the localization and intensity of immunohistochemical CK19 expression in CSTPTC and its associations with the clinical and pathological characteristics of patients with CSTPTC in the Silesian region.

Material and methods. All the available clinical and histopathological data for 149 patients with CSTPTC from the Silesian region were retrospectively analyzed. The group consisted of 135 (90.6%) women and 14 (9.4%) men (mean age and SD: 52.3 ± 15.0). All these patients with CSTPTC underwent surgery at the same center between 2008 and 2013; the follow-up period was 24 to 90 months (mean and SD: 47 ± 20).

Results. In 142 (95.3%) of the patients with CSTPTC, positive cytoplasmic staining of CK19 was found. A higher expression of CK19 was observed in the group of patients without the recurrence of the disease (p = 0.015). CK19 expression was not associated with age, gender, tumor focality, disease stage, tumor size (pT), lymph node involvement (pN), or distant metastases (pM).

Conclusions. Decreased CK19 expression in CSTPTC cases with relapse suggests that it plays a role in the carcinoma progression of CSTPTC. The association between lower CK19 expression and patients’ unfavorable postoperative course could suggest its possible role as a marker of CSTPTC poor prognosis.

Abstract

Introduction. Cytokeratin-19 (CK19) is recognized as a reliable tumor marker of papillary thyroid carcinoma (PTC). The general prognosis in the classical subtype of PTC (CSTPTC) remains favorable, but some cases can be very aggressive. The aim of this study was to evaluate the localization and intensity of immunohistochemical CK19 expression in CSTPTC and its associations with the clinical and pathological characteristics of patients with CSTPTC in the Silesian region.

Material and methods. All the available clinical and histopathological data for 149 patients with CSTPTC from the Silesian region were retrospectively analyzed. The group consisted of 135 (90.6%) women and 14 (9.4%) men (mean age and SD: 52.3 ± 15.0). All these patients with CSTPTC underwent surgery at the same center between 2008 and 2013; the follow-up period was 24 to 90 months (mean and SD: 47 ± 20).

Results. In 142 (95.3%) of the patients with CSTPTC, positive cytoplasmic staining of CK19 was found. A higher expression of CK19 was observed in the group of patients without the recurrence of the disease (p = 0.015). CK19 expression was not associated with age, gender, tumor focality, disease stage, tumor size (pT), lymph node involvement (pN), or distant metastases (pM).

Conclusions. Decreased CK19 expression in CSTPTC cases with relapse suggests that it plays a role in the carcinoma progression of CSTPTC. The association between lower CK19 expression and patients’ unfavorable postoperative course could suggest its possible role as a marker of CSTPTC poor prognosis.

Get Citation

Keywords

papillary thyroid carcinoma; cytokeratin 19; prognosis; IHC

About this article
Title

Expression of cytokeratin-19 (CK19) in the classical subtype of papillary thyroid carcinoma: the experience of one center in the Silesian region

Journal

Folia Histochemica et Cytobiologica

Issue

Vol 54, No 4 (2016)

Article type

Original paper

Pages

193-201

Published online

2016-12-22

DOI

10.5603/FHC.a2016.0025

Pubmed

28051274

Bibliographic record

Folia Histochem Cytobiol 2016;54(4):193-201.

Keywords

papillary thyroid carcinoma
cytokeratin 19
prognosis
IHC

Authors

Krzysztof Kaliszewski
Dorota Diakowska
Marta Strutynska-Karpinska
Marta Rzeszutko
Jedrzej Grzegrzolka
Piotr Dziegiel
Beata Wojtczak
Krzysztof Sutkowski

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl